CPL500036 - high dose

DRUG2 trials

Sponsors

Celon Pharma SA

Conditions

Dyskinesia, Medication-InducedParkinson DiseaseSchizophrenia

Phase 2

Efficacy, Safety and Pharmacokinetics Study of CPL500036 (PDE10A Inhibitor) in Patients With Schizophrenia

CompletedNCT05278156

Celon Pharma SASchizophrenia

Start: 2021-05-19End: 2024-06-19Updated: 2025-09-10

Efficacy, Safety and Pharmacokinetic Study of CPL500036 in Patients with Levodopa Induced Dyskinesia

CompletedNCT05297201

Celon Pharma SADyskinesia, Medication-Induced, Parkinson Disease

Start: 2021-11-02End: 2025-01-27Updated: 2025-03-04

Related Papers

PDE10A Inhibition in Schizophrenia: A Randomised, Placebo-Controlled Phase 2 Study of Alofropodect (CPL'36) in Patients Experiencing Acute Schizophrenia.

2026-07-31